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There is a substantial unmet clinical need for new strategies to protect the hematopoietic stem cell (HSC) pool and regenerate hematopoiesis after radiation injury from either cancer therapy or accidental exposure 1, 2 . Increasing evidence suggests that sex hormones, beyond their role in promoting sexual dimorphism, regulate HSC self-renewal, differentiation, and proliferation [3] [4] [5] . We and others have previously reported that sex-steroid ablation promotes bone marrow (BM) lymphopoiesis and HSC recovery in aged and immunodepleted mice [5] [6] [7] . Here we found that a luteinizing hormone (LH)-releasing hormone antagonist (LHRH-Ant), currently in wide clinical use for sex-steroid inhibition, promoted hematopoietic recovery and mouse survival when administered 24 h after an otherwise-lethal dose of total-body irradiation (L-TBI). Unexpectedly, this protective effect was independent of sex steroids and instead relied on suppression of LH levels. Human and mouse long-term self-renewing HSCs (LT-HSCs) expressed high levels of the LH/choriogonadotropin receptor (LHCGR) and expanded ex vivo when stimulated with LH. In contrast, the suppression of LH after L-TBI inhibited entry of HSCs into the cell cycle, thus promoting HSC quiescence and protecting the cells from exhaustion. These findings reveal a role of LH in regulating HSC function and offer a new therapeutic approach for hematopoietic regeneration after hematopoietic injury.
BM toxicity is a common dose-limiting side-effect of most cancer therapies and is the primary cause of death for victims of accidental radiation exposure. Despite intensive efforts to identify effective treatments for hematopoietic recovery and mitigation of radiation injury, available noncellular approaches remain limited 8 . Although several cytokines and growth factors have shown radioprotective properties when administered before radiation exposure, few are effective in mitigating radiation toxicity in a postinjury setting, thus restricting their application to the worst-case scenarios of nuclear accidents or terrorist attacks 9 .
Inhibition of sex steroids, which can be achieved pharmacologically in a reversible fashion, is a well-described strategy for promoting lymphopoiesis in the BM and thymus 6, 7, 10, 11 . Although the most common clinical method of sex-steroid ablation has been through use of LHRH agonists, we have previously proposed that use of LHRH antagonists may be a more rational approach to achieve immediate sex-steroid ablation for immune regeneration, for two reasons: LHRH antagonism is more rapid than agonism, and antagonism abrogates the initial surge in sex steroids caused by agonism 12 . On the basis of these findings, together with previous evidence of the effects of sexsteroid inhibition on HSC function and the rapid hormonal suppression mediated by LHRH antagonism, we hypothesized that an LHRH antagonist, when administered after hematopoietic insult, might provide a rational noncellular medical countermeasure for mitigating radiation injury and promoting hematopoietic regeneration.
To test this hypothesis, we administered to male mice an L-TBI dose of 840 cGy, which resulted in lethality in more than 90% of the mice (Supplementary Fig. 1a) . Mice receiving the LHRH-Ant (degarelix), compared with control mice treated with vehicle alone, showed significantly greater survival 24 h after L-TBI exposure (Fig. 1a) . Mouse lethality was a result of BM failure, because transplantation of BM Lin − Sca1 + c-Kit + (LSK) cells 3 d after L-TBI completely rescued mouse lethality (Supplementary Fig. 1b) . Despite similar decreases in cellularity across both treatment groups during the first 10 d, complete-blood-count analysis revealed that cellularity recovered only in mice treated with LHRH-Ant after L-TBI (Fig. 1b) , in agreement with the survival data. We next tested whether administration of multiple doses of LHRH-Ant might mediate even greater mouse survival. Perhaps unsurprisingly, given that hormone levels are abrogated within 24 h after administration 12 , treatment of mice 24 h and 15 d after L-TBI did not significantly enhance the survival benefit (Supplementary Fig. 1c) . Treatment with LHRH-Ant significantly enhanced mouse survival even when administered 48 h after L-TBI (Fig. 1c) , albeit with less effectiveness than that of administration at 24 h (Fig. 1a) , thus further validating this treatment as a potent medical countermeasure for lethal hematopoietic radiation exposure. Notably, we also found a statistically significant survival benefit in female mice treated with LHRH-Ant after L-TBI (Supplementary Fig. 1d ), although this effect was more modest than the benefit observed in male mice; this difference may potentially have been due to the differential effects of estrogen and testosterone on HSC function 4, 5 .
In agreement with the peripheral-blood recovery of mice treated with LHRH-Ant (Fig. 1b) , the BM cellularity of mice treated with this compound was significantly different from that of the control mice starting at day 14 after L-TBI (Fig. 1d) . Next, to determine the effects of LHRH-Ant on the recovery of committed hematopoietic progenitor cells, we quantified BM activity in colony-forming units. Whereas there was no difference in total BM cellularity at day 7 between LHRH-Ant and vehicle-treated L-TBI mice, BM-derived colony-forming-unit precursor of granulocyte/macrophage (CFU-GM) and burst-forming unit of erythroid cells (BFU-E) colony numbers were significantly higher in the mice treated with LHRH-Ant (Fig. 1e) . On day 14 after L-TBI, there was also a greater number of LSKs and their downstream progenitors in LHRH-Ant-treated mice, as well as significantly more LT-HSCs, which are crucial for sustained hematopoiesis (Fig. 1f,g ). Given that the HSC phenotype is known to be altered by radiation 13 , we also adapted the standard competitive repopulation assay to evaluate the presence and relative quantity of functional HSCs after L-TBI. Taking into account the potential for mobilization of HSCs after radiation exposure 14 , we collected all cells from the BM and spleen in vehicle-or LHRH-Ant-treated mice at day 14 after L-TBI and transplanted them into irradiated hosts (along with a rescue dose of congenic whole-BM cells to ensure recipient-mouse survival). This approach allowed us to establish the effects of LHRHAnt treatment on the total number of functional residual HSCs. Mice receiving cells from LHRH-Ant-treated L-TBI mice had significantly better hematopoietic reconstitution than did mice receiving cells from vehicle-treated control L-TBI mice (Fig. 1h,i and Supplementary  Fig. 2 ), thus suggesting that greater numbers of functional HSCs persisted in mice treated with LHRH-Ant. Analysis of the multilineage contribution of donor cells revealed that the increase in hematopoietic reconstitution was driven primarily by cells of lymphoid lineage, particularly B cells (Supplementary Fig. 2c ), Together, these data suggest that pharmacological inhibition of the LHRH receptor mitigates TBI-induced mortality and myelosuppression through protection and recovery of the HSC compartment.
Given the previous reports linking sex steroids to HSC function 5,7 , our initial hypothesis was that LHRH-Ant might facilitate hematopoietic recovery after radiation exposure through androgen ablation. To test this hypothesis and to gain insight into the mechanisms driving the regenerative effects of LHRH-Ant, we performed surgical castration in male mice and followed their survival after L-TBI. Unexpectedly, surgical castration did not protect mice from radiation injury, but simultaneous treatment of castrated mice with LHRH-Ant promoted mouse survival (Fig. 2a) . However, because surgery needed to be performed 5 d before TBI to ensure recovery by the time of irradiation, we could not exclude the possibility that our findings might have been confounded by the functional effects on HSCs of sexsteroid ablation administered before radiation 4, 5 . To account for this possibility, we treated mice with the androgen receptor (AR) inhibitor enzalutamide (MDV3100) 24 h after L-TBI. In agreement with the data in surgically castrated mice, MDV3100 treatment alone did not result in a survival benefit, but combined treatment with MDV3100 and LHRH-Ant increased mouse survival (Fig. 2b) . Moreover, in line with the well-characterized toxic effects of radiotherapy and chemotherapy on gonads and fertility 15 , TBI alone drastically decreased the levels of testosterone in mice receiving either LHRH-Ant or vehicle control, but no significant differences in testosterone levels were observed between these two groups (Fig. 2c) . These data strongly suggest that the beneficial effects of LHRH-Ant on hematopoiesis and survival post irradiation are sex-steroid independent.
Because LHRH exerts its effects in the pituitary, we next examined the effects of LHRH-Ant treatment on LH and follicle stimulating hormone (FSH), through which LHRH affects sex steroids. In contrast to testosterone levels, which were abrogated after TBI, LH levels decreased gradually, and FSH levels were not affected (Fig. 2c) . As expected, the levels of LH and FSH were significantly lower in irradiated mice given LHRH-Ant treatment than in those treated with vehicle ( Fig. 2c) . Given these effects on hormone levels after TBI, we analyzed mRNA expression of Ar as well as of the LH/choriogonadotropin receptor (Lhcgr) and FSH receptor (Fshr) in purified populations of HSPCs. We found almost no detectable expression of Ar or Fshr in any of the HSPC subsets examined, including primitive HSCs (Fig. 2d) . In contrast, expression of Lhcgr was highly enriched in LT-HSCs and was found at levels comparable to those in the testes (Fig. 2d) . Notably, we observed a similar Lhcgr expression pattern in the HSPCs of female mice (Supplementary Fig. 3b ). Further analysis revealed that Lhcgr expression was specific to LT-HSCs, and little or no expression was found in purified BM cells comprising the hematopoietic niche (Supplementary Fig. 3c ). These findings were consistent with data in publically accessible gene expression databases (The Immunological Genome Project and Gene Expression Commons). Using recently identified surface markers enabling granular characterization of the human HSC compartment 16 (Supplementary Fig. 3d ), we found that LHCGR expression was significantly enriched on the most primitive HSPC subsets, HSC1 (Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + ) and HSC2 (CD34 + CD38 − CD45RA − CD90 − CD49f + ); in contrast, expression was nearly absent on downstream multipotent progenitors (MPPs) and multilymphoid progenitors (MLPs) (Fig. 2e,f) . Although Lhcgr expression has previously been demonstrated in a crude fraction of Lin − CD45 + Sca1 + cells 3 , its enriched expression in the most primitive HSCs has not previously been reported, to our knowledge.
Given the restriction of Lhcgr expression to primitive HSCs, we sought to definitively determine whether the regenerative effects of LHRH-Ant treatment depend specifically on LH suppression, by testing whether stimulation of Lhcgr would abrogate the beneficial effects of LHRH-Ant treatment. For these studies, we used the alternative Lhcgr ligand human chorionic gonadotropin (hCG), because its half-life is longer than that of LH, and it is frequently used to stimulate LHCGR in mice 17 . In agreement with our hypothesis, hCG administration abrogated the beneficial effects of LHRH-Ant on survival after radiation injury (Fig. 2g) . Given the negative effects of LH signaling during hematopoietic recovery after radiation, we hypothesized that mice deficient in Lhcgr wouldbe protected from irradiation. We found that Lhcgr-knockout (KO) mice, compared with littermate-control mice, had a small but statistically significant increase in survival after L-TBI exposure (Fig. 2h) . In agreement with the modest increase in survival observed in Lhcgr-KO mice, analysis of hematopoietic recovery 14 d after L-TBI revealed only trends toward greater numbers of LT-HSCs and peripheral-blood counts in Lhcgr-KO mice (Supplementary Fig. 4a,b) . However, in a less extreme model of hematopoietic injury through a sublethal dose of TBI (SL-TBI, 550 cGy), we demonstrated a significant increase in the number of LT-HSCs in Lhcgr-KO mice (Supplementary Fig. 4c ). Complete blood counts of selected mice in a at day 0 (n = 6), day 7 (n = 7 vehicle-treated and 10 LHRH-Ant-treated mice), day 10 (n = 6 vehicle-treated and 6 LHRH-Ant-treated mice), day 14 (n = 11 vehicle-treated and 12 LHRH-Ant-treated mice), day 24 (n = 5 LHRH-Ant-treated mice), and day 150 (n = 6 LHRH-Ant-treated mice). Data combined from at least two independent experiments. WBC, white blood cells; RBC, red blood cells. (c) Survival of C57BL/6 male mice treated with LHRH-Ant or vehicle 48 h after L-TBI (840 cGy) (n = 15 mice per group). Data combined from two independent experiments. (d) BM cell counts of the mice in a at day 0 (n = 11 mice), day 7 (n = 11 mice per group), day 10 (n = 5 vehicle-treated and 6 LHRH-Ant-treated mice), day 14 (n = 8 vehicle-treated and 9 LHRH-Ant-treated mice), day 24 (n = 5 LHRH-Ant-treated mice), and day 150 (n = 7 LHRH-Ant-treated mice). Data combined from at least two independent experiments. (e) CFC colonies of BM cells from vehicle or LHRH-Ant-treated mice (n = 10 mice per group) at day 7 after L-TBI. Data combined from two independent experiments. (f) Concatenated FACS plots and representative gating strategies for the experiment in g (concatenated from three mice). The control of HSC self-renewal, differentiation, and proliferation is a tightly regulated process crucial for maintaining the HSC pool [18] [19] [20] [21] [22] . Maintenance of the HSC pool is particularly relevant in the context of hematopoietic injury, such as high-dose or repeated rounds of chemotherapy or irradiation, when dormant HSCs transiently proliferate and replenish blood cells; in contrast, unbalanced HSC proliferation can lead to stem cell exhaustion and long-term myelosuppression [23] [24] [25] . In agreement with its previously described role in promoting the proliferation of cells, including gonadal and neuronal cells 26, 27 , LH substantially enhanced colony formation of LSK cells in cobblestone-area-forming cell (CAFC) and colony-forming cell (CFC) assays (Fig. 3a,b) . Notably, LH also significantly expanded human umbilical cord blood (UCB) HSCs (CD34 + CD133 + CD45RA − CD90 + ) in vitro in a stroma-free culture system ( Fig. 3c and Supplementary Fig. 5a ); these expanded HSCs maintained robust primary and secondary colony-forming potential (Fig. 3d) . Although there is a clear need for HSC proliferation to ensure regenerative hematopoiesis 28 , previous reports have also shown that induction of HSC quiescence after high-dose irradiation correlates with improved hematopoietic recovery and enhanced mouse survival 23, 25, 29, 30 . In agreement with this notion, when we analyzed the cell-cycle status of HSCs in LHRHAnt-treated mice after L-TBI, we found a significantly higher proportion of Ki-67 − quiescent LT-HSCs (CD150 + CD48 − LSK) in the BM in the LHRH-Ant-treated group than the vehicle group ( Fig. 3e and Supplementary Fig. 5b ). Despite the smaller proportion of proliferating HSCs, LHRH-Ant treatment did not affect the absolute number of Ki-67 + HSCs (data not shown). This result, together with the lack of an effect of LHRH-Ant treatment on MPP proliferation h g (Testosterone: day 0, n = 3; vehicle day 7, n = 3; vehicle day 14, n = 9. LHRH-Ant: day 7, n = 4; day 14, n = 9. LH: untreated, n = 7; vehicle day 2, n = 8; vehicle day 7, n = 8; vehicle day 14, n = 4. LHRHAnt: day 2, n = 8; day 7, n = 7; day 14, n = 4. FSH: untreated, n = 6; vehicle day 2, n = 3; vehicle day 7, n = 5; vehicle day 14, n = 4. LHRH-Ant: day 2, n = 3; day 7, n = 4; day 14, n = 4 mice). Data combined from at least two independent experiments. (d) Expression of Ar, Lhcgr, and Fshr, assessed through qPCR in sorted LT-HSCs, short-term HSCs (ST-HSC), MPPs, MPs and whole BM (WBM) from untreated C57BL/6 male mice (n = 3 biological replicates, each pooled from 2 mice). Data represent one out of two independent experiments with similar findings. The gating strategy for each population is shown in Supplementary Figure 3a . Expression in one whole testis was assessed as a positive control. Data are plotted as relative quantification normalized to the levels of HPRT and β-actin. ( Supplementary Fig. 5c ), suggested that proliferating HSCs contribute to the effects of LHRH-Ant treatment after TBI on early hematopoiesis, notably the increases in MPP number and HSPC function ( Fig. 1e-g ). Mechanistically, inhibition of LH signaling retains HSCs in a quiescent phase and protects them from LH-induced entry into the cell cycle after high-dose irradiation.
To further test this hypothesis, we used two additional models to induce HSCs out of quiescence: polyinosinic:polycytidylic acid (poly(I:C)) and SL-TBI. To eliminate any potential effects of downstream sex steroids on HSCs, all mice in these studies were surgically castrated before any study-associated treatment. In agreement with our hypothesis, ablation of LH production with LHRH-Ant resulted in a significantly higher number of LT-HSCs in G 0 in both models (Fig. 3f,g and Supplementary Fig. 6 ). To evaluate whether promotion of HSC quiescence resulted in increased cell viability after radiation exposure, we analyzed cell apoptosis through annexin V staining and DAPI nuclear staining. Using the same administration scheme shown in Figure 3g , we found that LHRH-Ant treatment, compared with vehicle treatment, led to a significant increase in the proportion of live LT-HSCs (Fig. 3h) .
To gain insight into the molecular effects of LHRH-Ant treatment in HSCs, we purified LT-HSCs from mice after SL-TBI (300 cGy) with or without LHRH-Ant treatment and assessed the expression of key genes associated with quiescence, proliferation, the DNA-damage response and apoptosis of HSCs. Broadly, we observed that LT-HSCs derived from LHRH-Ant-treated mice, compared with those from vehicle-treated mice, showed significant overexpression of genes related to quiescence and apoptosis (P = 0.02 and P = 0.004, respectively) (Fig. 4a) . Within these categories, we found significantly higher levels of Hes1 and Cdkn1a (also known as p21), two genes previously identified to be critical in promoting HSC quiescence 22, 31 , as well as significantly higher levels of the antiapoptotic genes Bcl2 and Mcl1. Notably, Bcl2 and Mcl1 have been implicated in regulating HSC quiescence and survival, respectively 32, 33 .
To test whether the effects of LHRH-Ant on HSC quiescence and survival after hematopoietic stress might confer protection against chemotherapy-induced myeloablation, we challenged mice with successive doses of 5-fluorouracil (5-FU). Serial 5-FU treatment, a well-established method to functionally test HSC proliferation and self-renewal by ablating proliferating HSCs, ultimately leads to BM failure and death of treated mice 18, 22 . Abrogation of LH production significantly improved survival after serial 5-FU challenge (Fig. 4b) , thus supporting the concept that LHRH-Ant treatment promotes HSC quiescence and survival.
To evaluate the cell intrinsic effects of LHCGR stimulation in HSCs, we created hematopoietic chimeras, using LT-HSCs from wild type (WT) or KiLHR D582G mice as donor cells. KiLHR D582G mice carry a gain-of-function mutation (D582G) in LHCGR that confers constitutive activity 27 (Fig. 4c) . Peripheral-blood analysis of donor-cell reconstitution did not reveal differences between the two types of donor cells during the time course analyzed, thus suggesting that constitutive LHCGR signaling does not have substantial effects on HSC repopulating potential and survival (Fig. 4d) . We hypothesized that stimulation of the LHCGR might be detrimental to HSCs that proliferate after hematopoietic injury. To test this hypothesis, we exposed chimeric mice 6 months after transplantation to SL-TBI and evaluated HSC apoptosis 2 d later. In agreement with our previous findings, constitutive LHCGR signaling in KiLHR D582G HSCs, compared with LT-HSC WT cells, resulted in a significant decrease in LT-HSC survival after radiation exposure, as indicated by a significantly higher proportion of apoptotic cells (Fig. 4e) .
Together, our data demonstrate that pharmacological inhibition of LH signaling, as achieved in mice through a single dose of an LHRH antagonist, is a rational and feasible approach to preserve the HSC pool after high-dose radiation, thereby mitigating acute hematopoietic radiation syndrome. Contrary to our initial hypothesis, this effect was not mediated by sex steroids but instead was due to inhibition of LH signaling in the most primitive HSCs. Although HSC proliferation is clearly critical for regeneration after injury, there is a growing consensus that treatments that promote HSC quiescence immediately after damage can aid in mitigating HSC exhaustion and ultimately promote hematopoietic recovery 18, 22, 23, 25, 30, 34, 35 . We found that LHRH-Ant treatment restrained entry of HSCs into the cell cycle after hematopoietic insult and promoted the expression of genes associated with HSC quiescence, including Hes1 and p21 (refs. 22,31) . Particularly notable was the elevated expression of p21; this protein is redundant in HSCs in steady-state conditions but plays a crucial prosurvival role after hematopoietic stress 22, 36, 37 . We also observed elevated expression of the antiapoptotic genes Bcl2 and Mcl1, which have been implicated in regulating HSC quiescence and survival, respectively 32, 33 . , n = 7; 3 months, n = 8; 4 months, n = 10; 5 months, n = 4; 6 months, n = 9; 8 months, n = 5. KiLHR D582G : 1 month, n = 6; 2 months, n = 7; 3 months, n = 5; 4 months, n = 6; 5 months, n = 3; 6 months, n = 8; 8 months, n = 4 mice). Data are combined from at least two independent experiments. (e) The mice in d were exposed to 550-cGy radiation, and LT-HSCs were subjected to annexin V and DAPI analysis by FACS 2 d later (n = 8 mice per group). Data are combined from two independent experiments. (f) Schematic model of the proposed mechanism by which LHRH-Ant promotes HSC recovery after hematopoietic insult. For a, d, and e, data are displayed as the mean ± s.e.m. Statistics in a and e were generated with unpaired nonparametric two-tailed MannWhitney U tests; statistics in b were calculated with the Mantel-Cox (log-rank) test.
The ability of LHRH-Ant treatment to rescue mice after they have received a hematopoietic lethal dose of TBI indicates that some HSCs must survive the initial hit of radiation. We propose that these remaining HSCs must proliferate to regenerate hematopoiesis, but a combination of cell exhaustion and intracellular damage leads to their apoptosis and ultimately to BM failure and death of the mice. By inducing quiescence and/or by inhibiting apoptosis, LHRH-Ant prevents HSC exhaustion, thereby promoting long-term persistent hematopoiesis (Fig. 4f) .
In addition to these direct effects of LH on HSCs, other effects of LHRH-Ant might potentially contribute to hematopoietic recovery. In particular, widespread effects due to systemic hormonal ablation are likely to occur after LHRH-Ant treatment. We have previously shown that androgen suppression through surgical castration has substantial beneficial effects on the BM environment and on HSC function 7 , and several other groups have recently reported the regulation of HSC self-renewal and proliferation by estrogen 4, 5 . Hematopoietic radiation injury leads to HSC senescence, as manifested by myeloid skewing of HSCs and a markedly decreased longterm repopulation capacity 21, 38 , both of which are also hallmark traits of aging HSCs 39 . Notably, androgen ablation (via surgical castration) has been found to directly promote T and B lymphopoiesis in male mice and to reverse age-related declines in HSC function 11 . Thus, the combinatory events of enhanced HSC quiescence (mediated by LH suppression) and enhanced hematopoietic support from the BM niche (mediated by androgen suppression) may cooperate in promoting HSC recovery and survival of mice after L-TBI. Importantly, these secondary effects of androgen and estrogen ablation may also explain the differential effects of LHRH-Ant treatment on the survival of male and female mice.
Together, these findings not only offer a rational and safe medical countermeasure to treat hematopoietic radiation injury, using a drug already FDA approved for other indications, but also demonstrate a previously unrecognized role of LH signaling in the regulation of HSC homeostasis.
MeTHodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
oNLINe MeTHodS
Mice. Inbred male or female C57BL/6 (CD45.2) or B6.SJL-Ptprc a Pepc b /BoyJ (CD45.1) mice were obtained from the Jackson Laboratories and were used at 7 to 12 weeks of age. Lhcgr-KO mice were provided by Z.L. KiLHR D582G mice 27 were provided by P.N. Total-body irradiation was performed with a Gammacell 40 irradiator (Cs-137), with an approximate average dose rate of 95 cGy/min, in a Plexiglas mouse pie cage with mice placed in individual chambers. In assessment of mouse survival after radiation, mice were monitored for up to 60 d after TBI. Mouse cages were randomly allocated to each group before the start of the experiment, and all studies were approved by the Memorial Sloan Kettering Cancer Center or Fred Hutchinson Cancer Research Center Institutional Animal Care and Use Committees.
Cell isolation and cord-blood processing. BM cells were flushed from intact femurs and tibias, and spleens were mashed with glass slides to generate singlecell suspensions. Unless otherwise stated, all cell numbers in this study were standardized as total counts per two legs or per spleen. Endosteal cells (for isolation of OBLs) were isolated by crushing flushed bones and digesting with 0.15% (w/v) collagenase (Roche) and 0.1% (w/v) DNase I (Roche) in RPMI-1640. Human cord blood was obtained from the New York Blood Center (New York) and the Swedish Medical Center (Seattle). Mothers signed an informed consent to allow collection of cord blood. Cord-blood samples were layered on a Ficoll-Paque gradient and processed according to the manufacturer's protocol. CD34 + cells were then enriched by magnetic separation with a human CD34 MicroBead kit (Miltenyi Biotec).
Reagents. Degarelix acetate (Firmagon, Ferring Pharmaceuticals), an LHRH antagonist, was administered to mice subcutaneously (s.c.) in a single dose of 40 mg/kg. To induce HSCs to leave quiescence, mice were given either TBI or poly(I:C) (InvivoGen) intraperitoneally (i.p.) at a dose of 5 mg/kg, as previously described 23, 40, 41 . For in vivo mouse studies, hCG (Cellsciences, cat no. CRC101 and Sigma, cat no. CG10) was administered s.c. to mice at a dose of 20 IU; MDV3100 (Selleckchem) was resuspended in a mixture of 45% PBS, 45% PEG, and 10% DMSO, and was administered daily to mice by oral gavage at a dose of 10 mg/kg; and 5-FU (InvivoGen) was administered i.p. at a dose of 150 mg/kg once every 7 d for 3 weeks, as previously described 18, 22, 42 . LH from human pituitary glands (Sigma, cat no. L6420) was used at the indicated concentrations for in vitro studies. The antibodies used in this study for flow cytometry and sorting are described in Supplementary Table 1. Flow cytometry was performed on an LSR II or ARIA II instrument (BD Biosciences) with FACSDiva Software (BD Biosceinces). For intracellular Ki-67 and DAPI staining, cells were stained for surface markers, fixed, and permeabilized with a Fixation/Permeabilization kit (eBioscience) according to the manufacturer's instructions. For annexin V/DAPI staining, cells were surface labeled, washed and incubated with anti-annexin V (BD Pharmingen) in Annexin V Binding Buffer (BD Pharmingen).
CFC and CAFC assays. Colony assays were performed as previously described with minor modifications 43 .
Mouse cells. For CFC assays in Figure 1e , BM nucleated cells were suspended in Iscove's modified Dulbecco's medium (Gibco) supplemented with 1.2% methylcellulose (Dow Chemicals), 30% FBS, 2 mM glutamine, 0.1 mM monothiolglycerol, 0.1 mg/ml hemin (Sigma), 0.05 mg gentamicin, 20 ng/mL murine c-Kit ligand (Amgen), 6 units/ml human Epogen (Amgen), and 20 ng/mL murine IL-3 (Pepro Tech), and plated at a concentration of 5 × 10 4 cell/mL, and colonies were scored after 10 d. When fewer BM nucleated cells were available, equal amounts of all of the BM cells available were plated. For CFC assays in Figure 3b , 3 × 10 3 purified LSK cells (Lin − Sca1 + c-Kit + ) were cultured in StemSpan (Stemcell Technologies) supplemented with SCF, TPO, and FLT3L (all by Peprotech; 2 ng/ml each). Fresh LH was added daily for the first 3 d of in vitro culture. After 7 d of culture, the cells were harvested and subjected to CFC bioassays. For CAFC assays, 2 × 10 3 purified LSK cells were cocultured with confluent MS-5 cells (kindly provided by K.J. Mori (Niigata University) 44 in α-MEM containing 12.5% FBS (Atlanta Biologicals), 12.5% horse serum (GE Health Life Science), 1 µM hydrocortisone (Sigma), and 5 × 10 −5 M 2-mercaptoethanol (Fisher Scientific). Half of the culture medium was replenished weekly, and, after 3 weeks of coculture, CAFCs were scored as phase-dark hematopoietic clones of at least five cells beneath the stromal layer, as observed with an inverted microscope.
Human cells. Human UCB CD34 + cells were enriched and cultured as previously described 45 with anti-CD34 microbeads (Miltenyi Biotech). Enriched and sort-purified CD34 + cells were cultured in StemSpan (Stemcell Technologies) supplemented with 100 U/ml penicillin streptomycin (Gibco by Life Technologies) and SCF, TPO, and FLT3L (all by Peprotech; 100 ng/ml each), with 50% exchange of culture medium on day 4. Fresh LH was added daily for the total duration of in vitro culture. For primary CFC assays, 400 sorted cells were seeded into 1 ml MethoCult H4435 (StemCell Technologies). Hematopoietic colonies were microscopically analyzed on the basis of morphology, shape, and color (hemoglobinized) after 12-14 d. For secondary CFC assays, cells were harvested, dissociated, washed, and seeded into 3.5 ml Methocult H4434, and colonies that arose were analyzed and quantified after 12-14 d without discrimination of colony subtypes.
Bone marrow transplantation. In the transplantation experiment described in Figure 1h , cells were collected from the BM (femurs and tibias from both legs) and spleens from CD45.2 + vehicle or LHRH-Ant-treated mice at day 14 after L-TBI. Cells were then enriched for HSCs by depletion of Lin + cells and then transplanted into irradiated (1100-cGy TBI, split dose) CD45.1 + hosts at a ratio of one donor to one recipient along with 2.5 × 10 5 CD45.1 + rescue whole-BM cells, through tail-vein injection. Donor chimerism was monitored monthly after transplantation. In the LSK transplant in Supplementary  Figure 1b , LSK cells from BM were FACS purified. In the experiments using KiLHR D582G donor cells in Figure 4c -e, LT-HSCs (LSK CD48 − CD150 + ) from WT or KiLHR D582G mice were FACS purified. 500 WT or KiLHR D582G LTHSCs (LSK CD48 − CD150 + ) were transplanted along with 2.5 × 10 5 CD45.1 + competitor whole-BM cells into lethally irradiated hosts.
Real-time PCR. Reverse-transcription PCR was performed with a QuantiTect reverse-transcription kit (Qiagen). For real-time PCR, specific primer and probe sets from Applied Biosystems were as follows: β-actin (Mm01205647_g1), HPRT (Mm00446968_m1), AR (Mm00442688_m1), FSHR (Mm00442819_ m1), and LHCGR (Mm00442931_m1). A custom-made RT 2 qPCR Primer Array (Qiagen) was used to assess the genes listed in Figure 4a : target-specific primers were designed and validated by the manufacturer. PCR was done on ABI 7500 (Applied Biosystems) or Step-One Plus (Applied Biosystems) instruments with TaqMan Universal PCR Master Mix (Applied Biosystems). Relative amounts of mRNA were calculated with the Ct method. For genes analyzed in Figure 4a , total RNA was isolated from LT-HSCs (Lin − Sca-1 + cKit + CD48 − CD150 + CD34 − CD135 − ) sorted directly into RLT buffer with an RNeasy Micro Kit (Qiagen). cDNA was generated with a SuperScript VILO cDNA Synthesis Kit (Thermo Fisher). Platinum SYBR Green qPCR SuperMix (Thermo Fisher) was used to amplify the PCR targets of the custom-made RT 2 qPCR Primer Array (Qiagen). Array plates were run on an Applied Biosystems QuantStudio 7 Flex thermocycler and analyzed with the ∆Ct method.
Statistics. Sample sizes were based on previously published work and preliminary studies; the effect size for each study was estimated, and required sample sizes were calculated with G*Power (v3.1.9.2) 46 for an α = 0.05 and β = 0.8. For each experiment, replicates are described in the figure legends. Where indicated in the figure legends, bars and error bars represent the mean + s.e.m. Briefly, for in vivo studies, statistics were performed on biologically independent replicates combined from at least two individual experiments (unless otherwise stated); for in vitro studies, biologically independent samples were plated in either triplicate or quadruplicate (as technical replicates), but statistics were performed only on biologically independent samples. No samples or animals were excluded from the analysis except for the mouse peripheral-blood analysis, in which outliers were detected before analysis with a two-sided Grubbs' test. Investigators were not blinded to experimental conditions, but for all lethal TBI studies, staff monitoring mice for survival were blinded to experimental treatments. For all statistical analysis, no assumption of normality was made, so nonparametric tests were used. Analysis of differences between two groups was done with Mann-Whitney U tests or Wilcoxon rank-sum tests, as appropriate; and for analysis of survival curves, statistics were generated with Mantel-Cox log-rank tests. Differential analyses of functional gene groups (quiescence, DNA damage, apoptosis, and cyclins) in Figure 4a were computed with Fisher's method. All tests performed were two sided, except for gene functional-group analysis. All statistics were calculated, and display graphs were generated in GraphPad 6. 
Data exclusions
Describe any data exclusions.
No samples or animals were excluded from the analysis except for mouse peripheral blood analysis where outliers were detected prior to the analysis with two-sided Grubbs' test for outliers (GraphPad).
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful. To ensure adequate power for statistical analysis at least five samples per group were tested. For each experiment, replicates are noted in the figure legends. Briefly: for in vivo studies, statistics were performed on biologically independent replicates combined from at least two individual experiments (unless otherwise stated); for in vitro studies, biologically independent samples were plated in either triplicate or quadruplicate (as a technical replicate) but statistics were performed only on biologically independent samples.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No specific method of randomization was used. However, for drug treatment experiments, mouse cages were randomly allocated to each group after balancing of age and sex. For experiments with control and genetically modified mice (LHCGR-KO or kiLHR), animals were first genotyped and then randomly assigned to each group after balancing of age and sex.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to the group allocation during the experiments. For the survival experiments, the mortality was assessed daily by research technicians in a blinded fashion.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Flow Cytometry samples were acquired using FACSDiva Software (version 6.1.2). Flow Cytometry data were analyzed using FlowJo (version 9.9.3 and 10.2). Graphs and statistical analyses were prepared using Graphpad Prism (version 6 and 7) or Microsoft Excel 2011. qPCR data were analyzed using Quanti Studio RealTime PCR Software (Version 1.1) (Figure 4a ), StepOne Plus Software (Version 2.2.2) (Figure 2d and S3b) or Biorad CFX Manager ( Figure S3c ). Figures were prepared using Adobe Illustrator CS6 and CC 2017.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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